Hayeon Baik

Hayeon Baik

Auto-generated profile, based on publicly available information

Hayeon Baik

St. Anna Children’s Cancer Research Institute (CCRI), Vienna, Austria

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2018 in Cancer Research
Verified
Journal Article
Open access
PDF file
HBHayeon Baik
Hayeon Baik
MBMathias Boulanger
Mathias Boulanger
MHMohsen Hosseini
Mohsen Hosseini
JKJulie Kowalczyk
Julie Kowalczyk
SZSonia Zaghdoudi
Sonia Zaghdoudi
GBGuillaume Bossis
Guillaume Bossis
Differentiation therapies using all-trans retinoic acid (ATRA) are highly efficient at treating acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML). However, their efficacy, if any, is limited in the case of non-APL AML. We report here that inhibition of SUMOylation, a posttranslational modification related to ubiquitination, restores the prodifferentiation and antiproliferative activities of retinoids in non-APL AML. Controlled inhibition of SUMOylation with the pharmacologic inhibitors 2-D08 or anacardic acid, or via overexpression of SENP deSUMOylases, enhanced the ATRA-induced expression of key genes involved in differentiation, proliferation, and apoptosis in non-APL AML cells. This activated ATRA-induced terminal myeloid differentiation and reduced cell proliferation and viability, including in AML cells resistant to chemotherapeutic drugs. Conversely, enhancement of SUMOylation via overexpression of the SUMO-conjugating enzyme Ubc9 dampened expression of ATRA-responsive genes and prevented differentiation. Thus, inhibition of the SUMO pathway is a promising strategy to sensitize patients with non-APL AML to retinoids and improve the treatment of this poor-prognosis cancer. Significance: SUMOylation silences key ATRA-responsive genes in nonpromyelocytic acute myeloid leukemias. Cancer Res; 78(10); 2601–13. ©2018 AACR.

6 December 2024 in Cancer Immunology Research
Verified
Journal Article
Open access
MBMichelle Claudine Buri
Michelle Claudine Buri
MSMohamed R. Shoeb
Mohamed R. Shoeb
ABAleksandr Bykov
Aleksandr Bykov
PRPeter Repiscak
Peter Repiscak
HBHayeon Baik
Hayeon Baik
EPEva Maria Putz
Eva Maria Putz
The term cancer immunoediting describes the dual role by which the immune system can suppress and promote tumor growth and is divided into three phases: elimination, equilibrium, and escape. The role of NK cells has mainly been attributed to the elimination phase. Here, we show that NK cells play a role in all three phases of cancer immunoediting. Extended co-culturing of DNA-barcoded mouse BCR/ABLp185+ B-cell acute lymphoblastic leukemia (B-ALL) cells with NK cells allowed for a quantitative measure of NK cell–mediated immunoediting. Although most tumor cell clones were efficiently eliminated by NK cells, a certain fraction of tumor cells harbored an intrinsic primary resistance. Furthermore, DNA barcoding revealed tumor cell clones with secondary resistance, which stochastically acquired resistance to NK cells. NK cell–mediated cytotoxicity put a selective pressure on B-ALL cells, which led to an outgrowth of primary and secondary resistant tumor cell clones, which were characterized by an IFNγ signature. Besides well-known regulators of immune evasion, our analysis of NK cell–resistant tumor cells revealed the upregulation of genes, including lymphocyte antigen 6 complex, locus A (Ly6a), which we found to promote leukemic cell resistance to NK cells. Translation of our findings to the human system showed that high expression of LY6E on tumor cells impaired their physical interaction with NK cells and led to worse prognosis in patients with leukemia. Our results demonstrate that tumor cells are actively edited by NK cells during the equilibrium phase and use different avenues to escape NK cell–mediated eradication.

17 June 2026
Verified
Other
Open access
MBMichelle Claudine Buri
Michelle Claudine Buri
MSMohamed R. Shoeb
Mohamed R. Shoeb
ABAleksandr Bykov
Aleksandr Bykov
PRPeter Repiscak
Peter Repiscak
HBHayeon Baik
Hayeon Baik
EPEva Maria Putz
Eva Maria Putz
Supplementary Figure S5: Extended quantification of NK cell-mediated cancer immunoediting in vitro.

17 June 2026
Verified
Other
Open access
MBMichelle Claudine Buri
Michelle Claudine Buri
MSMohamed R. Shoeb
Mohamed R. Shoeb
ABAleksandr Bykov
Aleksandr Bykov
PRPeter Repiscak
Peter Repiscak
HBHayeon Baik
Hayeon Baik
EPEva Maria Putz
Eva Maria Putz
Supplementary Figure S11: The expression of LY6E on K562 does not impact on IFN-γ or TNF-α production in NK cells.

17 June 2026
Verified
Other
Open access
MBMichelle Claudine Buri
Michelle Claudine Buri
MSMohamed R. Shoeb
Mohamed R. Shoeb
ABAleksandr Bykov
Aleksandr Bykov
PRPeter Repiscak
Peter Repiscak
HBHayeon Baik
Hayeon Baik
EPEva Maria Putz
Eva Maria Putz
Supplementary Table 2: Antibodies and viability dyes used for flow cytometric analyses and immunoblotting. Indicated are target antigens, conjugates, clones, suppliers, catalogue numbers, and used working dilutions.

17 June 2026
Verified
Other
Open access
MBMichelle Claudine Buri
Michelle Claudine Buri
MSMohamed R. Shoeb
Mohamed R. Shoeb
ABAleksandr Bykov
Aleksandr Bykov
PRPeter Repiscak
Peter Repiscak
HBHayeon Baik
Hayeon Baik
EPEva Maria Putz
Eva Maria Putz
Supplementary Figure S7: Analysis of differentially accessible genes in NK cell resistant tumour cells.